A Study to Identify a Panel of Biomarkers to Predict Response to Anti PD-1 Therapy

Overview

About this study

The purpose of this study is to identify a panel of possible biomarkers to predict response to anti PD-1 therapy by establishing the progression free survival rate at 6 months for cancer patients treated with anti PD-1 medications, then perform biopsies for biomarkers on saved tissue samples from these patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Had metastatic melanoma, renal cell carcinoma, non small cell lung cancer, or any other cancer
Underwent therapy with an anti-PD1 agent
Gave permission for use of archived tissue samples
Clinical data on treatment response is available

Exclusion Criteria

Were lost to follow up

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Roxana Dronca, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Roxana Dronca, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials